Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molecular targets and pathways for the treatment of visceral leishmaniasis
Vineet Jain, Keerti Jain
Drug Discovery Today (2017) Vol. 23, Iss. 1, pp. 161-170
Closed Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Flavonoids as efficient scaffolds: Recent trends for malaria, leishmaniasis, Chagas disease, and dengue
Boniface Pone Kamdem, Elizabeth Igne Ferreira
Phytotherapy Research (2019) Vol. 33, Iss. 10, pp. 2473-2517
Closed Access | Times Cited: 62
Antileishmanial Drug Discovery and Development: Time to Reset the Model?
Ana Isabel Olías-Molero, Concepción de la Fuente, Montserrat Cuquerella, et al.
Microorganisms (2021) Vol. 9, Iss. 12, pp. 2500-2500
Open Access | Times Cited: 56
Amphotericin B resistance in Leishmania mexicana: Alterations to sterol metabolism and oxidative stress response
Edubiel A. Alpizar-Sosa, Nur Raihana Ithnin, Wenbin Wei, et al.
PLoS neglected tropical diseases (2022) Vol. 16, Iss. 9, pp. e0010779-e0010779
Open Access | Times Cited: 33
Conjugates of amphotericin B to resolve challenges associated with its delivery
Vineet Jain, Keerti Jain, Harvinder Popli
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 2, pp. 187-210
Closed Access | Times Cited: 6
Emerging Trends and Promises of Nanoemulsions In Therapeutics Of Infectious Diseases
Mehak Juneja, Teeja Suthar, Vishwas P. Pardhi, et al.
Nanomedicine (2022) Vol. 17, Iss. 11, pp. 793-812
Closed Access | Times Cited: 21
Receptor-Targeted Surface-Engineered Nanomaterials for Breast Cancer Imaging and Theranostic Applications
Javed Ahmad, Md. Rizwanullah, Teeja Suthar, et al.
Critical Reviews in Therapeutic Drug Carrier Systems (2022) Vol. 39, Iss. 6, pp. 1-44
Open Access | Times Cited: 20
Leishmanicidal Activity of Guanidine Derivatives against Leishmania infantum
Fernanda Silva Almeida, Vitor Partite Moreira, Edson dos Santos Silva, et al.
Tropical Medicine and Infectious Disease (2023) Vol. 8, Iss. 3, pp. 141-141
Open Access | Times Cited: 12
One Platform Comparison of Polymeric and Lipidic Nanoparticles for the Delivery of Amphotericin B
Nandha Joyson, Anchal Pathak, Keerti Jain
AAPS PharmSciTech (2023) Vol. 24, Iss. 8
Closed Access | Times Cited: 12
Envisioning the Innovations in Nanomedicine to Combat Visceral Leishmaniasis: For Future Theranostic Application
Om Prakash Singh, Mallikarjuna Rao Gedda, Shyam Lal Mudavath, et al.
Nanomedicine (2019) Vol. 14, Iss. 14, pp. 1911-1927
Open Access | Times Cited: 33
Design, Hemisynthesis, Characterization, Molecular Docking, and Dynamics Evaluation of Novel Totarol‐1,2,3‐Triazole Derivatives as Leishmaniasis and Toxoplasmosis Agents
Ayoub Boualli, Yassine Laamari, Abdoullah Bimoussa, et al.
Chemical Biology & Drug Design (2025) Vol. 105, Iss. 2
Closed Access
Desenvolvimento de um agente anti-infeccioso com lausona para o tratamento da Tuberculose e Leishmaniose
Regina Maria Mendes Oliveira, Tatielle Gomes Dias, Fernanda Farias Costa, et al.
Cuadernos de Educación y Desarrollo (2025) Vol. 17, Iss. 4, pp. e7916-e7916
Closed Access
Targeting the Trypanothione Reductase of Tissue-Residing Leishmania in Hosts’ Reticuloendothelial System: A Flexible Water-Soluble Ferrocenylquinoline-Based Preclinical Drug Candidate
Debarati Mukherjee, Md Yousuf, Somaditya Dey, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 24, pp. 15621-15638
Closed Access | Times Cited: 27
Emerging strategies and challenges of molecular therapeutics in antileishmanial drug development
Deepak Gupta, Pankaj Kumar Singh, Pavan Kumar Yadav, et al.
International Immunopharmacology (2023) Vol. 115, pp. 109649-109649
Closed Access | Times Cited: 9
Efficient Dimerization Disruption of Leishmania infantum Trypanothione Reductase by Triazole-phenyl-thiazoles
Alejandro Revuelto, Héctor de Lucio, Juan Carlos García-Soriano, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 9, pp. 6137-6160
Open Access | Times Cited: 20
Targeting Leishmania infantum Mannosyl-oligosaccharide glucosidase with natural products: potential pH-dependent inhibition explored through computer-aided drug design
Luis Daniel Goyzueta-Mamani, Haruna Luz Barazorda-Ccahuana, Mayron Antonio Candia-Puma, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2
Outwitting an Old Neglected Nemesis: A Review on Leveraging Integrated Data-Driven Approaches to Aid in Unraveling of Leishmanicides of Therapeutic Potential
Samuel K. Kwofie, Emmanuel Broni, Bismark Dankwa, et al.
Current Topics in Medicinal Chemistry (2020) Vol. 20, Iss. 5, pp. 349-366
Closed Access | Times Cited: 17
Emerging concerns of infectious diseases and drug delivery challenges
Archana Bagre, Parth Patel, Saba Naqvi, et al.
Elsevier eBooks (2022), pp. 1-23
Closed Access | Times Cited: 11
Major Molecular Factors Related to Leishmania Pathogenicity
Hanan Al-Khalaifah
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 10
Leishmania spp. in indigenous populations: A mini-review
Louise Bach Kmetiuk, Thais Cristina Tirado, Leandro Meneguelli Biondo, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 9
Design and synthesis of imidazolidinone derivatives as potent anti‐leishmanial agents by bioisosterism
Dandugudumula Ramu, Ravi Jain, Ravi Kumar, et al.
Archiv der Pharmazie (2019) Vol. 352, Iss. 4
Closed Access | Times Cited: 13
Antileishmanial and cytotoxic activity of secondary metabolites from Taberneamontana ventricosa and two aloe species
Moses Andima, Albert Ndakala, Solomon Derese, et al.
Natural Product Research (2021) Vol. 36, Iss. 5, pp. 1365-1369
Open Access | Times Cited: 11
Bromodomain Factor 5 as a Target for Antileishmanial Drug Discovery
Catherine N. Russell, Jennifer Carter, Juliet M. Borgia, et al.
ACS Infectious Diseases (2023) Vol. 9, Iss. 11, pp. 2340-2357
Open Access | Times Cited: 4
GDP-Mannose Pyrophosphorylase: A Biologically Validated Target for Drug Development Against Leishmaniasis
Sébastien Pomel, Wei Mao, Tâp Ha‐Duong, et al.
Frontiers in Cellular and Infection Microbiology (2019) Vol. 9
Open Access | Times Cited: 11
An overview of the fatty acid biosynthesis in the protozoan parasite Leishmania and its relevance as a drug target against leishmaniasis
Richa Arya, Chetna Dhembla, Ravindra D. Makde, et al.
Molecular and Biochemical Parasitology (2021) Vol. 246, pp. 111416-111416
Closed Access | Times Cited: 10
In vitro evaluation against Leishmania amazonensis and Leishmania chagasi of medicinal plant species of interest to the Unified Health System
Lilyana Waleska Nunes Albuquerque, SHAKIRA C.A. FERREIRA, Izabelly Carollynny Maciel Nunes, et al.
Anais da Academia Brasileira de Ciências (2024) Vol. 96, Iss. 3
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top